Tenax Therapeutics, Inc. (TENX) SEC filings

TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30

$1.62+0.01 (+0.62%)

Close on Nov 13, 2026Market cap $60.63MP/E –Yield –

SEC filings

40 of Tenax Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Oct 8, 2026	Oct 8, 2026	SEC EDGAR
Current report	8-K	Sep 9, 2026	Sep 9, 2026	SEC EDGAR
Current report	8-K	Aug 10, 2026	Aug 10, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Jul 31, 2026	SEC EDGAR
Current report	8-K	Jul 31, 2026	Jul 31, 2026	SEC EDGAR
Current report	8-K	Jul 2, 2026	Jul 2, 2026	SEC EDGAR
Current report	8-K	Jun 29, 2026	Jun 30, 2026	SEC EDGAR
Current report	8-K	Jun 26, 2026	Jun 29, 2026	SEC EDGAR
Current report	8-K	Jun 2, 2026	Jun 4, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 12, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 17, 2026	Apr 22, 2026	SEC EDGAR
Current report	8-K	Apr 22, 2026	Apr 22, 2026	SEC EDGAR
Current report	8-K	Mar 10, 2026	Mar 10, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 10, 2026	SEC EDGAR
Current report	8-K	Jan 6, 2026	Jan 9, 2026	SEC EDGAR
Current report	8-K	Dec 17, 2025	Dec 17, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Sep 16, 2025	Sep 16, 2025	SEC EDGAR
Current report	8-K	Sep 3, 2025	Sep 9, 2025	SEC EDGAR
Current report	8-K	Aug 13, 2025	Aug 13, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Jun 11, 2025	Jun 17, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 14, 2025	SEC EDGAR
Proxy statement	DEF 14A	Apr 24, 2025	Apr 25, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 25, 2025	SEC EDGAR
Current report	8-K	Mar 25, 2025	Mar 25, 2025	SEC EDGAR
Current report	8-K	Mar 4, 2025	Mar 6, 2025	SEC EDGAR
Current report	8-K	Dec 2, 2024	Dec 4, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Nov 13, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Oct 25, 2024	Oct 30, 2024	SEC EDGAR
Proxy statement	DEF 14A	Oct 25, 2024	Sep 27, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Aug 13, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Aug 12, 2024	Aug 12, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Tenax Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-80 reverse split on Jan 3, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TENX.

Compare: TENX vs NAMS · TENX vs LQDA · TENX vs GOSS · TENX vs EWTX · TENX vs TVRD

Company	Revenue	Growth
LQDA	$621.87M	+798.4%
GOSS	$78.42M	+78.0%
NAMS	$25.94M	-26.4%
TENX	$0	–
EWTX	–	–
TVRD	–	–

Company

Next earnings (est.): Mar 9, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 14
Held by institutions: 81.1%
Auditor: Cherry Bekaert LLP
SEC CIK: 34956

Advertisement
300 × 250

See a number that looks wrong?